MAZE THERAPEUTICS INC (MAZE) — insider trading
Health Care · NASDAQ
MAZE THERAPEUTICS INC (MAZE) has 98 reported SEC Form 4 insider transactions in our data, including 53 open-market sales among the most recent 98 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 31,908 | $27.02 | $862.2K | Form 4 |
| 2026-10-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 2,593 | $27.02 | $70.1K | Form 4 |
| 2026-10-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion (derivative) | 16,141 | — | $0 | Form 4 |
| 2026-10-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 16,141 | $26.93 | $434.7K | Form 4 |
| 2026-10-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion | 16,141 | $10.42 | $168.2K | Form 4 |
| 2026-09-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-09-29 | Dandekar Atul | Officer (CSBO) | Open-market sale | 7,500 | $27.06 | $202.9K | Form 4 |
| 2026-09-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 7,500 | $10.42 | $78.2K | Form 4 |
| 2026-09-04 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 9,705 | $26.22 | $254.5K | Form 4 |
| 2026-09-03 | Dandekar Atul | Officer (CSBO) | Open-market sale | 36 | $25.81 | $929 | Form 4 |
| 2026-09-03 | Dandekar Atul | Officer (CSBO) | Open-market sale | 3,207 | $26.01 | $83.4K | Form 4 |
| 2026-09-03 | Courtney Phillips | Officer (GC and Corp. Secretary) | Open-market sale | 22 | $25.78 | $567 | Form 4 |
| 2026-09-03 | Courtney Phillips | Officer (GC and Corp. Secretary) | Open-market sale | 1,990 | $26.01 | $51.8K | Form 4 |
| 2026-09-03 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 129 | $25.77 | $3.3K | Form 4 |
| 2026-09-03 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 11,282 | $26.01 | $293.5K | Form 4 |
| 2026-09-03 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 59 | $25.78 | $1.5K | Form 4 |
| 2026-09-03 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 5,130 | $26.01 | $133.4K | Form 4 |
| 2026-09-02 | Dandekar Atul | Officer (CSBO) | Open-market sale | 391 | $27.12 | $10.6K | Form 4 |
| 2026-09-02 | Dandekar Atul | Officer (CSBO) | Open-market sale | 2,800 | $26.38 | $73.9K | Form 4 |
| 2026-09-02 | Courtney Phillips | Officer (GC and Corp. Secretary) | Open-market sale | 243 | $27.12 | $6.6K | Form 4 |
| 2026-09-02 | Courtney Phillips | Officer (GC and Corp. Secretary) | Open-market sale | 1,738 | $26.38 | $45.8K | Form 4 |
| 2026-09-02 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 1,375 | $27.12 | $37.3K | Form 4 |
| 2026-09-02 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 9,852 | $26.38 | $259.9K | Form 4 |
| 2026-09-02 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 625 | $27.12 | $17.0K | Form 4 |
| 2026-09-02 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 4,481 | $26.38 | $118.2K | Form 4 |
| 2026-09-01 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-09-01 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 12,500 | — | $0 | Form 4 |
| 2026-09-01 | Courtney Phillips | Officer (GC and Corp. Secretary) | Option exercise / conversion (derivative) | 11,000 | — | $0 | Form 4 |
| 2026-09-01 | Courtney Phillips | Officer (GC and Corp. Secretary) | Option exercise / conversion | 11,000 | — | $0 | Form 4 |
| 2026-09-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-09-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Option exercise / conversion | 50,000 | — | $0 | Form 4 |
| 2026-09-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 31,908 | $26.29 | $838.8K | Form 4 |
| 2026-09-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 2,593 | $26.31 | $68.2K | Form 4 |
| 2026-09-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-09-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion (derivative) | 16,141 | — | $0 | Form 4 |
| 2026-09-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion | 20,000 | — | $0 | Form 4 |
| 2026-09-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 16,141 | $26.36 | $425.5K | Form 4 |
| 2026-09-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion | 16,141 | $10.42 | $168.2K | Form 4 |
| 2026-08-28 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-08-28 | Dandekar Atul | Officer (CSBO) | Open-market sale | 7,500 | $27.58 | $206.8K | Form 4 |
| 2026-08-28 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 7,500 | $10.42 | $78.2K | Form 4 |
| 2026-08-13 | Johnson Paula A | Director | Grant / award / vesting (derivative) | 36,000 | — | $0 | Form 4 |
| 2026-08-13 | Kornowski Sophie | Director | Grant / award / vesting (derivative) | 36,000 | — | $0 | Form 4 |
| 2026-08-13 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion (derivative) | 16,142 | — | $0 | Form 4 |
| 2026-08-13 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 16,142 | $27.61 | $445.6K | Form 4 |
| 2026-08-13 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion | 16,142 | $10.42 | $168.2K | Form 4 |
| 2026-08-03 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 1,604 | $27.09 | $43.4K | Form 4 |
| 2026-08-03 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 30,304 | $26.71 | $809.5K | Form 4 |
| 2026-08-03 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 154 | $27.09 | $4.2K | Form 4 |
| 2026-08-03 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 2,439 | $26.71 | $65.2K | Form 4 |
| 2026-07-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-07-29 | Dandekar Atul | Officer (CSBO) | Open-market sale | 400 | $27.89 | $11.2K | Form 4 |
| 2026-07-29 | Dandekar Atul | Officer (CSBO) | Open-market sale | 7,100 | $27.31 | $193.9K | Form 4 |
| 2026-07-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 7,500 | $10.42 | $78.2K | Form 4 |
| 2026-07-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 1,597 | $30.44 | $48.6K | Form 4 |
| 2026-07-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 30,311 | $29.95 | $907.9K | Form 4 |
| 2026-07-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 2,593 | $29.98 | $77.7K | Form 4 |
| 2026-07-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion (derivative) | 14,609 | — | $0 | Form 4 |
| 2026-07-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 1,200 | $30.34 | $36.4K | Form 4 |
| 2026-07-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 13,409 | $29.87 | $400.5K | Form 4 |
| 2026-07-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion | 14,609 | $10.42 | $152.2K | Form 4 |
| 2026-06-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-06-29 | Dandekar Atul | Officer (CSBO) | Open-market sale | 7,500 | $28.02 | $210.2K | Form 4 |
| 2026-06-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 7,500 | $10.42 | $78.2K | Form 4 |
| 2026-06-23 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 23,865 | $26.05 | $621.7K | Form 4 |
| 2026-06-22 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 2,040 | $26.00 | $53.0K | Form 4 |
| 2026-06-22 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 1,953 | $26.00 | $50.8K | Form 4 |
| 2026-06-08 | Andrews Nancy C | Director | Grant / award / vesting (derivative) | 18,000 | — | $0 | Form 4 |
| 2026-06-08 | HOMCY CHARLES J | Director | Grant / award / vesting (derivative) | 18,000 | — | $0 | Form 4 |
| 2026-06-08 | Hoppenot Herve | Director | Grant / award / vesting (derivative) | 18,000 | — | $0 | Form 4 |
| 2026-06-08 | Lim Jonathan E | Director | Grant / award / vesting (derivative) | 18,000 | — | $0 | Form 4 |
| 2026-06-08 | SCHELLER RICHARD H | Director | Grant / award / vesting (derivative) | 18,000 | — | $0 | Form 4 |
| 2026-06-08 | SPIEGELMAN DANIEL K | Director | Grant / award / vesting (derivative) | 18,000 | — | $0 | Form 4 |
| 2026-06-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion (derivative) | 14,853 | — | $0 | Form 4 |
| 2026-06-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 1,600 | $26.36 | $42.2K | Form 4 |
| 2026-06-01 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 13,253 | $25.57 | $338.9K | Form 4 |
| 2026-06-01 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion | 14,853 | $10.42 | $154.8K | Form 4 |
| 2026-06-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 553 | $26.24 | $14.5K | Form 4 |
| 2026-06-01 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 6,090 | $26.20 | $159.5K | Form 4 |
| 2026-05-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-05-29 | Dandekar Atul | Officer (CSBO) | Open-market sale | 7,500 | $26.34 | $197.6K | Form 4 |
| 2026-05-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 7,500 | $10.42 | $78.2K | Form 4 |
| 2026-05-26 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 25,582 | $26.02 | $665.5K | Form 4 |
| 2026-05-22 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 2,478 | $26.00 | $64.4K | Form 4 |
| 2026-05-22 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 4,504 | $26.00 | $117.1K | Form 4 |
| 2026-05-15 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 116 | $26.00 | $3.0K | Form 4 |
| 2026-05-15 | Coloma Jason V | Director, Officer (Chief Executive Officer) | Open-market sale | 1,822 | $26.00 | $47.4K | Form 4 |
| 2026-05-14 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion (derivative) | 15,000 | — | $0 | Form 4 |
| 2026-05-14 | Bernstein Harold | Officer (President, R&D & CMO) | Open-market sale | 15,000 | $26.22 | $393.4K | Form 4 |
| 2026-05-14 | Bernstein Harold | Officer (President, R&D & CMO) | Option exercise / conversion | 15,000 | $10.42 | $156.3K | Form 4 |
| 2026-05-04 | HOMCY CHARLES J | Director | Bona fide gift | 7,422 | — | $0 | Form 4 |
| 2026-05-04 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 5,985 | — | $0 | Form 4 |
| 2026-05-04 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 8,320 | — | $0 | Form 4 |
| 2026-05-04 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 5,985 | $10.42 | $62.4K | Form 4 |
| 2026-05-04 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 8,320 | $10.42 | $86.7K | Form 4 |
| 2026-04-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion (derivative) | 7,500 | — | $0 | Form 4 |
| 2026-04-29 | Dandekar Atul | Officer (CSBO) | Open-market sale | 7,500 | $25.37 | $190.3K | Form 4 |
| 2026-04-29 | Dandekar Atul | Officer (CSBO) | Option exercise / conversion | 7,500 | $10.42 | $78.2K | Form 4 |
Ask the chat about MAZE's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MAZE THERAPEUTICS INC (MAZE).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.